Fulgent Genetics, Inc. (FLGT) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2026-02-27

How it makes money

It earns revenue by performing diagnostic tests and providing pathology services to patients, healthcare providers, and biopharmaceutical companies.

Hospitals, physicians, and biopharma clients pay for specialized genetic tests, anatomic pathology, and precision diagnostics. Profitability moves with the volume of tests ordered, test complexity, and pricing terms negotiated with diverse payers.

Reimbursement collection success and the specific mix of tests delivered each period heavily influence overall financial results.

What protects it: the moat

It protects its market position using proprietary technology platforms, specialized gene probes, and artificial intelligence software integrated into workflows.

Management asserts that proprietary gene probes, comparison algorithms, and custom image management systems lower the cost per test and drive high laboratory efficiency. However, intense competition and fluctuating customer concentrations mean these claimed advantages must continually defend against rivals.

Intellectual property acquired through transactions like the ANP buyout also aims to secure ownership over clinical development platforms.

What growth costs

It reinvests capital into laboratory acquisitions, therapeutic pipeline development, and the purchase of tax credits to expand operations.

The filing notes capital expenditures for laboratory infrastructure alongside corporate acquisitions such as Bako, StrataDx, and ANP. Additionally, it directs capital toward research and development for therapeutic drug delivery platforms and acquiring Investment Tax Credits.

The business incurs significant expenses complying with heavy regulatory requirements across its laboratory network.

What could damage it

Government audits, billing infractions, or denied insurance claims could trigger severe monetary penalties and exclude it from Medicare and Medicaid programs.

If billing practices violate government healthcare regulations, agencies can impose steep financial penalties and demand refunds from ongoing audits or investigations. Because collections depend on successful claims submissions, losing access to major government reimbursement programs would directly impair operating earnings.

About Fulgent Genetics, Inc.

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.

Other companies in Diagnostics & Research